- Home
- EVRI vs AGIO Comparison
EVRI vs AGIO Comparison
Compare EVRI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRI
- AGIO
- Stock Information
- Founded
- EVRI 1998
- AGIO 2007
- Country
- EVRI United States
- AGIO United States
- Employees
- EVRI N/A
- AGIO N/A
- Industry
- EVRI Services-Misc. Amusement & Recreation
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- EVRI Consumer Discretionary
- AGIO Health Care
- Exchange
- EVRI Nasdaq
- AGIO Nasdaq
- Market Cap
- EVRI 1.2B
- AGIO 1.4B
- IPO Year
- EVRI 2005
- AGIO 2013
- Fundamental
- Price
- EVRI $13.77
- AGIO $27.66
- Analyst Decision
- EVRI Hold
- AGIO Buy
- Analyst Count
- EVRI 4
- AGIO 8
- Target Price
- EVRI $12.83
- AGIO $56.57
- AVG Volume (30 Days)
- EVRI 1.9M
- AGIO 745.1K
- Earning Date
- EVRI 05-07-2025
- AGIO 05-01-2025
- Dividend Yield
- EVRI N/A
- AGIO N/A
- EPS Growth
- EVRI N/A
- AGIO N/A
- EPS
- EVRI 0.17
- AGIO 11.64
- Revenue
- EVRI $757,903,000.00
- AGIO $36,498,000.00
- Revenue This Year
- EVRI $3.49
- AGIO $41.13
- Revenue Next Year
- EVRI $4.01
- AGIO $234.96
- P/E Ratio
- EVRI $81.00
- AGIO $2.38
- Revenue Growth
- EVRI N/A
- AGIO 36.07
- 52 Week Low
- EVRI $6.37
- AGIO $23.42
- 52 Week High
- EVRI $13.83
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- EVRI 58.61
- AGIO 44.94
- Support Level
- EVRI $13.17
- AGIO $26.87
- Resistance Level
- EVRI $13.62
- AGIO $28.24
- Average True Range (ATR)
- EVRI 0.16
- AGIO 1.94
- MACD
- EVRI 0.03
- AGIO 0.22
- Stochastic Oscillator
- EVRI 95.24
- AGIO 66.15
About EVRI Everi Holdings Inc.
Everi Holdings Inc provides entertainment and technology solutions for the casino, interactive, and gaming industry. It operates in two segments namely Games and Financial Technology Solutions (FinTech). Enveri Games provides gaming operators with gaming technology products and services which include gaming machines, slot machines, leased gaming equipment, and other products and services. Enveri FinTech provides gaming operators with financial technology products and services which include services and equipment that facilitate casino patron's to access cash at gaming facilities through automated teller machines, point of sale debit card purchases and others.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.